Bladder pain relief by HMGB1 neutralization and soluble thrombomodulin in mice with cyclophosphamide-induced cystitis

Neuropharmacology

Volumn 79, Issue , 2014, Pages 112-118

  Tanaka, Junichi ^a,b   Yamaguchi, Kaoru ^a   Ishikura, Hiroyasu ^b   Tsubota, Maho ^a   Sekiguchi, Fumiko ^a   Seki, Yukari ^a   Tsujiuchi, Toshifumi ^a   Murai, Akira ^b   Umemura, Takehiro ^b   Kawabata, Atsufumi ^a  

^a KINKI UNIVERSITY   (Japan)

^b FUKUOKA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Bladder pain; Cystitis; High mobility group box 1 (HMGB1); Receptor for advanced glycation end products (RAGE); Thrombomodulin; Visceral pain

Indexed keywords

ADVANCED GLYCATION END PRODUCT; CYCLOPHOSPHAMIDE; HIGH MOBILITY GROUP B1 PROTEIN; HIGH MOBILITY GROUP B1 PROTEIN ANTIBODY; LOW MOLECULAR WEIGHT HEPARIN; NEUTRALIZING ANTIBODY; RECOMBINANT THROMBOMODULIN; UNCLASSIFIED DRUG; ANALGESIC AGENT; HEPARIN; HMGB1 PROTEIN, MOUSE; IMMUNOLOGIC FACTOR; LIPOPOLYSACCHARIDE; THBD PROTEIN, HUMAN; THROMBOMODULIN;

ANALGESIC ACTIVITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYSTALGIA; CYSTITIS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG TARGETING; DRUG TISSUE LEVEL; FEMALE; HYPERALGESIA; MOUSE; NONHUMAN; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; TISSUE LEVEL; ANIMAL; BLADDER; BLOOD; DRUG EFFECTS; HUMAN; IMMUNOLOGY; METABOLISM; NOCICEPTIVE PAIN; ORGAN SIZE; PAIN; PAIN, REFERRED; PATHOLOGY; PATHOPHYSIOLOGY; RHODOBACTER SPHAEROIDES; UROTHELIUM;

ANALGESICS; ANIMALS; ANTIBODIES, NEUTRALIZING; CYCLOPHOSPHAMIDE; CYSTITIS; FEMALE; HEPARIN; HMGB1 PROTEIN; HUMANS; HYPERALGESIA; IMMUNOLOGIC FACTORS; LIPOPOLYSACCHARIDES; MICE; NOCICEPTIVE PAIN; ORGAN SIZE; PAIN; PAIN, REFERRED; RHODOBACTER SPHAEROIDES; THROMBOMODULIN; URINARY BLADDER; UROTHELIUM;

EID: 84890021259     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2013.11.003     Document Type: Article

References (28)

1. P.J. Baker, C.E. Taylor, P.W. Stashak, M.B. Fauntleroy, K. Haslov, N. Qureshi, and K. Takayama Inactivation of suppressor T cell activity by the nontoxic lipopolysaccharide of Rhodopseudomonas sphaeroides Infect. Immun. 58 1990 2862 2868
2. M. Chacur, E.D. Milligan, L.S. Gazda, C. Armstrong, H. Wang, K.J. Tracey, S.F. Maier, and L.R. Watkins A new model of sciatic inflammatory neuritis (SIN): induction of unilateral and bilateral mechanical allodynia following acute unilateral peri-sciatic immune activation in rats Pain 94 2001 231 244
3. J. Evankovich, S.W. Cho, R. Zhang, J. Cardinal, R. Dhupar, L. Zhang, J.R. Klune, J. Zlotnicki, T. Billiar, and A. Tsung High mobility group box 1 release from hepatocytes during ischemia and reperfusion injury is mediated by decreased histone deacetylase activity J. Biol. Chem. 285 2010 39888 39897
4. P. Feldman, M.R. Due, M.S. Ripsch, R. Khanna, and F.A. White The persistent release of HMGB1 contributes to tactile hyperalgesia in a rodent model of neuropathic pain J. Neuroinflamm. 9 2012 180
5. W. Huang, Y. Tang, and L. Li HMGB1, a potent proinflammatory cytokine in sepsis Cytokine 51 2010 119 126
6. T. Ito, K. Kawahara, K. Okamoto, S. Yamada, M. Yasuda, H. Imaizumi, Y. Nawa, X. Meng, B. Shrestha, T. Hashiguchi, and I. Maruyama Proteolytic cleavage of high mobility group box 1 protein by thrombin-thrombomodulin complexes Arterioscler Thromb. Vasc. Biol. 28 2008 1825 1830
7. T. Ito, and I. Maruyama Thrombomodulin: protectorate god of the vasculature in thrombosis and inflammation J. Thromb. Haemost. 9 Suppl. 1 2011 168 173
8. J.M. Laird, V. Souslova, J.N. Wood, and F. Cervero Deficits in visceral pain and referred hyperalgesia in Nav1.8 (SNS/PN3)-null mice J. Neurosci. 22 2002 8352 8356
9. Y.H. Li, C.H. Kuo, G.Y. Shi, and H.L. Wu The role of thrombomodulin lectin-like domain in inflammation J. Biomed. Sci. 19 2012 34
10. R. Liu, S. Mori, H. Wake, J. Zhang, K. Liu, Y. Izushi, H.K. Takahashi, B. Peng, and M. Nishibori Establishment of in vitro binding assay of high mobility group box-1 and S100A12 to receptor for advanced glycation endproducts: heparin's effect on binding Acta Med. Okayama 63 2009 203 211
11. T. Liu, Y.J. Gao, and R.R. Ji Emerging role of toll-like receptors in the control of pain and itch Neurosci. Bull. 28 2012 131 144
12. I.K. Lukic, P.M. Humpert, P.P. Nawroth, and A. Bierhaus The RAGE pathway: activation and perpetuation in the pathogenesis of diabetic neuropathy Ann. N. Y Acad. Sci. 1126 2008 76 80
13. C.S. Malarkey, and M.E. Churchill The high mobility group box: the ultimate utility player of a cell Trends Biochem. Sci. 37 2012 553 562
14. 2+ channel pathway in cystitis-related bladder pain in mice Br. J. Pharmacol. 167 2012 917 928
15. T. Miki, M. Matsunami, S. Nakamura, H. Okada, H. Matsuya, and A. Kawabata ONO-8130, a selective prostanoid EP1 receptor antagonist, relieves bladder pain in mice with cyclophosphamide-induced cystitis Pain 152 2011 1373 1381
16. M. Mohri, Y. Gonda, M. Oka, Y. Aoki, K. Gomi, T. Kiyota, T. Sugihara, S. Yamamoto, T. Ishida, and I. Maruyama The antithrombotic effects of recombinant human soluble thrombomodulin (rhsTM) on tissue factor-induced disseminated intravascular coagulation in crab-eating monkeys (Macaca fascicularis) Blood Coagul. Fibrinolysis 8 1997 274 283
17. K.M. Myint, Y. Yamamoto, T. Doi, I. Kato, A. Harashima, H. Yonekura, T. Watanabe, H. Shinohara, M. Takeuchi, K. Tsuneyama, N. Hashimoto, M. Asano, S. Takasawa, H. Okamoto, and H. Yamamoto RAGE control of diabetic nephropathy in a mouse model: effects of RAGE gene disruption and administration of low-molecular weight heparin Diabetes 55 2006 2510 2522
18. T. Olivar, and J.M. Laird Cyclophosphamide cystitis in mice: behavioural characterisation and correlation with bladder inflammation Eur. J. Pain 3 1999 141 149
19. K. Otoshi, S. Kikuchi, K. Kato, M. Sekiguchi, and S. Konno Anti-HMGB1 neutralization antibody improves pain-related behavior induced by application of autologous nucleus pulposus onto nerve roots in rats Spine (Phila Pa 1976) 36 2011 E692 E698
20. P.C. Ren, Y. Zhang, X.D. Zhang, L.J. An, H.G. Lv, J. He, C.J. Gao, and X.D. Sun High-mobility group box 1 contributes to mechanical allodynia and spinal astrocytic activation in a mouse model of type 2 diabetes Brain Res. Bull. 88 2012 332 337
21. M. Shibasaki, M. Sasaki, M. Miura, K. Mizukoshi, H. Ueno, S. Hashimoto, Y. Tanaka, and F. Amaya Induction of high mobility group box-1 in dorsal root ganglion contributes to pain hypersensitivity after peripheral nerve injury Pain 149 2010 514 521
22. G.P. Sims, D.C. Rowe, S.T. Rietdijk, R. Herbst, and A.J. Coyle HMGB1 and RAGE in inflammation and cancer Annu. Rev. Immunol. 28 2010 367 388
23. A. Takeuchi, Y. Yamamoto, S. Munesue, A. Harashima, T. Watanabe, H. Yonekura, H. Yamamoto, and H. Tsuchiya Low molecular weight heparin suppresses receptor for advanced glycation end products-mediated expression of malignant phenotype in human fibrosarcoma cells Cancer Sci. 104 2013 740 749
24. W. Tong, W. Wang, J. Huang, N. Ren, S.X. Wu, and Y.Q. Li Spinal high-mobility group box 1 contributes to mechanical allodynia in a rat model of bone cancer pain Biochem. Biophys. Res. Commun. 395 2010 572 576
25. H. Wang, O. Bloom, M. Zhang, J.M. Vishnubhakat, M. Ombrellino, J. Che, A. Frazier, H. Yang, S. Ivanova, L. Borovikova, K.R. Manogue, E. Faist, E. Abraham, J. Andersson, U. Andersson, P.E. Molina, N.N. Abumrad, A. Sama, and K.J. Tracey HMG-1 as a late mediator of endotoxin lethality in mice Science 285 1999 248 251
26. C. Wantuch, M. Piesla, and L. Leventhal Pharmacological validation of a model of cystitis pain in the mouse Neurosci. Lett. 421 2007 250 252
27. L.R. Watkins, M.R. Hutchinson, K.C. Rice, and S.F. Maier The "toll" of opioid-induced glial activation: improving the clinical efficacy of opioids by targeting glia Trends Pharmacol. Sci. 30 2009 581 591
28. H. Yanai, T. Ban, and T. Taniguchi High-mobility group box family of proteins: ligand and sensor for innate immunity Trends Immunol. 33 2012 633 640